^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
New
Source:
Title:

Alpha-fetoprotein (AFP) response in patients with unresectable hepatocellular carcinoma (HCC) in the phase III RESORCE trial

Excerpt:
Serum AFP levels were assessed at baseline, every 4 weeks during treatment, and at the end of treatment. Patients who had a baseline AFP ≥20 ng/mL and an AFP measurement at the start of Cycle 3 were evaluable for AFP response, defined as a decrease of ≥ 20% in AFP level from baseline at the start of Cycle 3....In this exploratory analysis of RESORCE, an AFP response with regorafenib was associated with improved OS.
DOI:
10.1093/annonc/mdz247.081
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levels

Published date:
11/16/2021
Excerpt:
The median overall survival (OS) with regorafenib was 12.4 months (95% CI, 7.8-17.0) and the median progression-free survival (PFS) was 4.2 months (95% CI, 3.7-4.7)…Patients possessing baseline AFP < 400 ng/ml exhibited a markedly longer median OS, median PFS, and higher DCR compared with their counterparts...The results of this real-world study verified the tolerability and efficacy of regorafenib treatment for uHCC patients...
DOI:
10.1002/cam4.4430
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

952P - Prognostic implication of serum alpha-fetoprotein in patients with unresectable hepatocellular carcinoma treated with regorafenib

Published date:
09/13/2021
Excerpt:
Patients with on-treatment AFP response (n=196, 34%) had significantly longer OS and PFS than those without AFP response….Baseline AFP and on-treatment AFP response were independent prognostic factors for advanced HCC patients treated with regorafenib.